Cyteir Therapeutics (Cyteir Therapeutics) Net Income

: $-33.22 Mil (TTM As of Sep. 2023)

View and export this data going back to 2021. Start your Free Trial

Net Income is the net profit that a company earns after deducting all costs and losses including cost of goods, SGA, DDA, interest expenses, non-recurring items and tax. Cyteir Therapeutics's Net Income for the three months ended in Sep. 2023 was $-3.53 Mil. Its Net Income for the trailing twelve months (TTM) ended in Sep. 2023 was $-33.22 Mil.

Net Income is linked to the most popular Earnings per Share (Diluted) number. Cyteir Therapeutics's Earnings per Share (Diluted) for the three months ended in Sep. 2023 was $-0.10.

Cyteir Therapeutics Net Income Historical Data

The historical data trend for Cyteir Therapeutics's Net Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cyteir Therapeutics Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Net Income

-15.04

-20.82

-42.13

-46.06

Cyteir Therapeutics Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
Net Income	Get a 7-Day Free Trial											-11.05	-8.79	-12.49	-8.40	-3.53

Cyteir Therapeutics Net Income Calculation

Net Income is the net profit that a company earns after deducting all costs and losses including cost of goods, SGA, DDA, interest expenses, non-recurring items and tax.

Net Income
= Revenue - Cost of Goods Sold - Selling, General, & Admin. Expense - Research & Development - Depreciation, Depletion and Amortization - Interest Expense - Non Operating Income (NRI) - Tax Expense + Others
= EBITDA - Depreciation, Depletion and Amortization - Interest Expense - Non Operating Income (NRI) - Tax Expense + Others
= Operating Income - Interest Expense - Non Operating Income (NRI) - Tax Expense + Others
= Pre-Tax Income - Tax Expense + Others

Cyteir Therapeutics's Net Income for the fiscal year that ended in Dec. 2022 is calculated as

	Net Income		(A: Dec. 2022 )
=	Pre-Tax Income	+	Tax Provision	+	Net Income (Discontinued Operations)	+	Others
=	-46.061	+	0	+	0	+	0
=	-46.06

Cyteir Therapeutics's Net Income for the quarter that ended in Sep. 2023 is calculated as

	Net Income		(Q: Sep. 2023 )
=	Pre-Tax Income	+	Tax Provision	+	Net Income (Discontinued Operations)	+	Others
=	-3.532	+	0	+	0	+	0
=	-3.53

Net Income for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-33.22 Mil.

Cyteir Therapeutics (OTCPK:CYTT) Net Income Explanation

Net Income is the most widely cited number in reporting a company's profitability. It is linked to the most popular earnings-per-share (EPS) number through:

Cyteir Therapeutics's Earnings per Share (Diluted) (EPS) for the quarter that ended in Sep. 2023 is calculated as

Earnings per Share (Diluted) (Q: Sep. 2023 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Diluted Average)
	=	(-3.532	-	0)	/	36.030
	=	-0.10

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

EPS is most useful for companies that have:

A predictable business
Consistent accounting methods
And few restructurings

The dividend paid to preferred stocks needs to be subtracted from the total net income in the calculation of EPS because common stock holders are not entitled to that part of the net income.

Be Aware

Warren Buffett looks for consistency and upward long term trend. Because of share repurchase it is possible for net earnings trend to differ from EPS trend. He preferred Net Income over EPS. The companies with durable competitive advantage companies report higher % net earnings to total revenues.

Important: If a company is showing net earnings history greater than 20% on total revenues, it is probably benefiting from a long term competitive advantage.

If net earnings is less than 10%, likely to be in a highly competitive business.

Cyteir Therapeutics Net Income Related Terms

Thank you for viewing the detailed overview of Cyteir Therapeutics's Net Income provided by GuruFocus.com. Please click on the following links to see related term pages.

Cyteir Therapeutics (Cyteir Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cyteir Therapeutics Inc (OTCPK:CYTT) » Definitions » Net Income

Comparable Companies

Traded in Other Exchanges

N/A

Address

128 Spring Street, Building A, Suite 510, Lexington, MA, USA, 02421

Website

https://www.cyteir.com

Cyteir Therapeutics Inc is a clinical-stage biotechnology company focused on the development of CYT-0851, an oral investigational drug that inhibits monocarboxylate transporters. CYT-0851 is an investigational monocarboxylate transporter inhibitor or MCT inhibitor, initially evaluated in a phase 1/2 study to treat patients with hematologic malignancies and solid tumors as a monotherapy and in combination with standard-of-care therapies. Inhibiting MCT function in glycolytic cancer cells leads to an accumulation of intracellular lactate that impairs glycolysis and inhibits tumor cell growth, making MCTs an attractive target for cancer therapy.

Executives

Novo Holdings A/s	10 percent owner	TUBORG HAVNEVEJ 19, HELLERUP G7 2900
Joseph S Zakrzewski	director	509 WATERVIEW PLACE, NEW HOPE PA 18938
John F Thero	director	C/O AMARIN PHARMA, INC., 1430 ROUTE 6, BEDMINSTER NJ 07921
Adam M Veness	officer: General Counsel	C/O DIANTHUS THERAPEUTICS, INC., 7 TIMES SQUARE, 43RD FLOOR, NEW YORK NY 10036
Stephen H. Sands	director	128 SPRING STREET, BUILDING A, SUITE 510, LEXINGTON MA 02421
Jeffrey Humphrey	director	C/O CONSTELLATION PHARMACEUTICALS, INC., 215 FIRST STREET, SUITE 200, CAMBRIDGE MA 02142
Droia Invest Ii Scsp	10 percent owner	28 BOULEVARD JOSEPH II, LUXEMBOURG N4 L-1840
Janwillem Naesens	director	128 SPRING STREET, BUILDING A, SUITE 510, LEXINGTON MA 02421
Sa Ihl	10 percent owner	28 BOULEVARD JOSEPH II, LUXEMBOURG N4 L-1840
Karen Hong	director	69 PARKSIDE DRIVE, PRINCETON NJ 08540
Bv Wepaven	10 percent owner	BRUSSELSESTEENWEG 11, MEISE C9 1860
Luc Verelst	10 percent owner	28 BOULEVARD JOSEPH II, LUXEMBOURG N4 L-1840
Df Ii Gp Sarl	10 percent owner	28 BOULEVARD JOSEPH II, LUXEMBOURG N4 L-1840
Timothy Romberger	director	128 SPRING STREET, BUILDING A, SUITE 510, LEXINGTON MA 02421
Racquel Bracken	director	128 SPRING STREET, BUILDING A, SUITE 510, LEXINGTON MA 02421